SeaStar Medical (NASDAQ:ICU) Releases Quarterly Earnings Results, Beats Expectations By $0.17 EPS

SeaStar Medical (NASDAQ:ICU) announced its quarterly earnings results on Wednesday. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.17, FiscalAI reports. The company had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.22 million. SeaStar Medical had a negative return on equity of 237.15% and a negative net margin of 984.60%.

Here are the key takeaways from SeaStar Medical’s conference call:

• SeaStar expanded QUELIMMUNE adoption to 16 top pediatric centers and reported over $1.1M in QUELIMMUNE product revenue for 2025 (Q4 $315k), targeting $2M in product revenue and ~15 additional top children’s hospitals in 2026.
• The NEUTRALIZE-AKI pivotal trial has enrolled 181 of 339 patients (>50%) with enrollment targeted by year-end 2026 and potential top-line results mid-2027, and the company has initiated a modular PMA submission while holding FDA Breakthrough Device designation for the adult AKI indication.
• Post‑approval real‑world data from the SAVE registry (initial 21‑patient publication; 50 patients enrolled) showed no device‑related adverse events and encouraging survival (76% at days 28/60; 71% at day 90), supporting QUELIMMUNE safety and adoption in pediatric AKI.
• Financially, SeaStar reported >90% gross margins on product sales, reduced operating expenses (FY2025 $13.4M vs $18M prior year), raised approximately $23.9M of capital in 2025 and ended the year with about $12M cash and no long‑term debt.
• Near‑term revenue upside is limited by the small pediatric AKI market (~$100M) and the company’s broader commercial opportunity depends on successful adult SCD approval and ongoing funding given 2025 net loss (~$12.2M) versus ~$12M year‑end cash.

SeaStar Medical Price Performance

Shares of ICU opened at $2.79 on Friday. The company has a 50-day simple moving average of $2.47 and a two-hundred day simple moving average of $4.06. The firm has a market capitalization of $10.57 million, a PE ratio of -0.34 and a beta of -1.04. SeaStar Medical has a one year low of $2.07 and a one year high of $25.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ICU shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, January 22nd. Wall Street Zen raised SeaStar Medical to a “hold” rating in a research note on Saturday, January 10th. Finally, Maxim Group set a $6.00 price target on shares of SeaStar Medical in a report on Thursday, February 12th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell” and an average target price of $6.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of SeaStar Medical during the third quarter valued at approximately $102,000. Jane Street Group LLC purchased a new stake in SeaStar Medical in the fourth quarter worth $30,000. Finally, XTX Topco Ltd raised its holdings in SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares in the last quarter. Hedge funds and other institutional investors own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.